Relationship between 233 colorectal cancer risk loci and survival in 1926 patients with advanced disease

[1]  Stephanie A. Bien,et al.  Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries , 2022, Nature Genetics.

[2]  R. Houlston,et al.  A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients. , 2021, European journal of cancer.

[3]  H. Campbell,et al.  Colorectal cancer risk variants rs10161980 and rs7495132 are associated with cancer survival outcome by a recessive mode of inheritance , 2021, International journal of cancer.

[4]  R. Houlston,et al.  Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants. , 2019, European journal of cancer.

[5]  Xinyu Wang,et al.  Down-regulation of UTP23 promotes paclitaxel resistance and predicts poorer prognosis in ovarian cancer. , 2019, Pathology, research and practice.

[6]  H. Campbell,et al.  Effects of common genetic variants associated with colorectal cancer risk on survival outcomes after diagnosis: A large population‐based cohort study , 2019, International journal of cancer.

[7]  Aung Ko Win,et al.  Association analyses identify 31 new risk loci for colorectal cancer susceptibility , 2019, Nature Communications.

[8]  W. Zheng,et al.  Colorectal cancer susceptibility loci and influence on survival , 2018, Genes, chromosomes & cancer.

[9]  C. Lindskog,et al.  A pathology atlas of the human cancer transcriptome , 2017, Science.

[10]  Latarsha J. Carithers,et al.  The Genotype-Tissue Expression (GTEx) Project. , 2015, Biopreservation and biobanking.

[11]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[12]  Aung Ko Win,et al.  A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer , 2015, Scientific Reports.

[13]  D. Kerr,et al.  Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival , 2015, Clinical Cancer Research.

[14]  Joris M. Mooij,et al.  MAGMA: Generalized Gene-Set Analysis of GWAS Data , 2015, PLoS Comput. Biol..

[15]  P. Broderick,et al.  A Retrospective Observational Study of the Relationship between Single Nucleotide Polymorphisms Associated with the Risk of Developing Colorectal Cancer and Survival , 2015, PloS one.

[16]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[17]  D. Sargent,et al.  Germline Variation in Colorectal Risk Loci Does Not Influence Treatment Effect or Survival in Metastatic Colorectal Cancer , 2014, PloS one.

[18]  Á. Carracedo,et al.  Genetic susceptibility variants associated with colorectal cancer prognosis. , 2013, Carcinogenesis.

[19]  S. Miyano,et al.  The rs6983267 SNP Is Associated with MYC Transcription Efficiency, Which Promotes Progression and Worsens Prognosis of Colorectal Cancer , 2013, Annals of Surgical Oncology.

[20]  H. Nan,et al.  Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival. , 2013, Carcinogenesis.

[21]  Kouros Owzar,et al.  Power and Sample Size Calculations for SNP Association Studies With Censored Time‐to‐Event Outcomes , 2012, Genetic epidemiology.

[22]  Christopher F. Martin,et al.  Association of Eleven Common, Low-Penetrance Colorectal Cancer Susceptibility Genetic Variants at Six Risk Loci with Clinical Outcome , 2012, PloS one.

[23]  L. Ellis,et al.  GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. , 2012, Carcinogenesis.

[24]  H. Nan,et al.  Association between colorectal cancer susceptibility loci and survival time after diagnosis with colorectal cancer. , 2012, Gastroenterology.

[25]  J. Marchini,et al.  Genotype Imputation with Thousands of Genomes , 2011, G3: Genes | Genomes | Genetics.

[26]  D. Lambrechts,et al.  Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011, The Lancet.

[27]  Harpreet Wasan,et al.  Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011, The Lancet. Oncology.

[28]  P. Broderick,et al.  The CDH1‐160C>A polymorphism is a risk factor for colorectal cancer , 2009, International journal of cancer.

[29]  P. Donnelly,et al.  A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies , 2009, PLoS genetics.

[30]  M. Takeichi,et al.  Cadherin cell adhesion receptors as a morphogenetic regulator. , 1991, Science.